Genetic architecture:The shape of the genetic contribution to human traits and disease by Timpson, Nicholas J et al.
                          Timpson, N. J., Greenwood, C. M. T., Soranzo, N., Lawson, D. J., &
Richards, J. B. (2018). Genetic architecture: The shape of the genetic
contribution to human traits and disease. Nature Reviews Genetics, 19(2),
110-124. https://doi.org/10.1038/nrg.2017.101
Peer reviewed version
Link to published version (if available):
10.1038/nrg.2017.101
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Nature Publishing Group at DOI: 10.1038/nrg.2017.101 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
  1 
Genetic architecture: the shape of the genetic contribution to human traits and disease 
 
Nicholas J. Timpson1, Celia M. T. Greenwood2,3, Nicole Soranzo4,5, Daniel J. Lawson1 & J. Brent Richards 
3,6,7  
 
1. MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of 
Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN, UK. 
2. Department of Oncology, McGill University, 3755 Cote Ste Catherine, Montreal, Quebec, Canada 
H3T 1E2 
3. Departments of Human Genetics and Epidemiology, Biostatistics and Occupational Health, 
McGill University, 3755 Cote Ste Catherine, Montreal, Quebec, Canada, H3T 1E2  
4. The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1HH, 
Cambridge, UK. 
5. Department of Haematology, University of Cambridge, Long Road, Cambridge CB2 0PT, UK. 
6. Department of Medicine, Jewish General Hospital, Lady Davis Institute, McGill University, 3755 
Cote Ste Catherine, Montreal, Quebec, Canada H3T 1E2  
7. Department of Twin Research & Genetic Epidemiology, King’s College London, St Thomas’ 
Campus, Lambeth Palace Road, London, SE1 7EH, UK. 
 
Correspondence to N. J. T. or J. B. R.: n.j.timpson@bristol.ac.uk; brent.richards@mcgill.ca 
 
  
Genetic architecture describes the characteristics of genetic variation that are responsible for 
heritable phenotypic variability. It depends on the number of genetic variants affecting a trait, 
their frequencies in the population, the magnitude of their effects, and their interactions with 
each other and the environment. Defining the genetic architecture of a complex trait or disease 
is central to the scientific and clinical goals of human genetics, which are to understand disease 
etiology and aid in disease screening, diagnosis, prognosis and therapy. Recent technological 
advances have enabled genome-wide association studies (GWAS) and emerging next-
generation sequencing studies to begin to decipher the nature of the heritable contribution to 
traits and disease. Here we describe the types of genetic architecture that have been observed, 
how architecture can be measured, and why an improved understanding of genetic architecture 
is central to future advances in the field and the influences that shape it. 
 
[H1] Introduction   
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It can be argued that most of the challenges and rewards in human genetics are dependent 
upon scientists understanding genetic architecture so that they can more fully describe what 
causes disease and translate this information to the clinic. The term ‘genetic architecture’ in 
human population-based studies describes the characteristics of genetic variation that are 
responsible for broad sense phenotypic heritability [G].1 Specifically, genetic architecture 
comprises the number of variants influencing a phenotype [G] , the magnitude of their effects on 
the phenotype, the population frequency of these variants and their interactions with each other 
and the environment.2 Thus, by contrast to narrow sense heritability, which only refers to the 
impact of additive genetic effects on complex traits [G] ,3 genetic architecture refers broadly to a 
complete understanding of all genetic contributions to a given trait or disease outcome, as well 
as to an awareness of the characteristics of this contribution.4 (Box 1) 
 
Human genomes can differ from one another at single genomic positions as single nucleotide 
variants [G] (SNVs), or they can exhibit larger structural changes including copy number 
variations, translocations and inversions5 (reviewed elsewhere6). To understand genetic 
architecture, variations in DNA sequence between genomes is tested for an association with 
phenotypic variability through gene-mapping studies, a field that has enjoyed success over the 
last decade.7 These association signal mapping studies have increasingly become genome-
wide association studies [G] (GWAS), whole-exome sequencing (WES) studies [G] and whole-
genome sequencing (WGS) studies [G]. 
 
GWAS use genome-wide genotyping arrays to measure genetic variation and they are the 
standard platform to test the association of a phenotype with common genetic variants. In this 
article, common genetic variants, low genetic variants and rare genetic variants are defined as 
those with a minor allele frequency [G] (MAF) of ≥5%, ≥1% but <5%, and <1%, respectively.8 
However, genotyping arrays can be designed to contain relatively rare variants. Furthermore, 
deep imputation [G] (discussed below) can be used to test phenotypic associations with 
additional low frequency and rare variants. As the least expensive modern genome-wide gene-
mapping method, GWAS has been successfully employed in large human populations and has 
allowed a much improved understanding of the direct association of common variants (that is, 
not through interactions) with complex traits and diseases.7 Many of these associations were 
found at non-coding variants, and these associations, including some that are driven by rare 
variants, were enriched at regulatory sites9,10 Indeed it is now thought that up to 85% of all 
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human common genetic variation is at least nominally associated with the expression of gene 
transcripts for protein coding genes.11  
 
WES can identify rare variants associated with a phenotype, but is restricted to examining the 
protein-coding content of the genome. Although WES can identify genetic variants that are likely 
to directly influence gene function, the exome represents only about 1% of the genome,12 and 
most disease-associated genetic variants that have been identified lie outside the exome.7 WGS 
can measure nearly all genetic variation in the human genome and assess structural variants 
more accurately than WES,13 but it costs much more than it. It is currently not possible to 
sequence all regions of the genome with equal quality. For example, regions with highly 
repetitive DNA are difficult to assess14 and, therefore, not all genomic variation is captured by 
WGS. Furthermore, due to their cost, WGS studies have been limited by sample size and 
consequently may miss rare variants. However, the recent availability of large-scale cohort 
resources, such as the UKBiobank15 and TopMed16 programmes, combined with concurrent 
advances in WES, WGS and GWAS, will facilitate a more precise description of the contribution 
of low frequency and rare genetic variants to the genetic architecture of complex traits and 
disease.17 Of note, GWAS, WES and WGS can also be used to estimate the narrow sense 
heritability of a trait or disease, and the resulting estimates have often been lower than those 
from classical twin heritability studies, which estimate heritability by contrasting the similarity in 
phenotypes between monozygotic and dizygotic twins. This has been reviewed previously18 and 
this is therefore not a topic of this review. 
 
Genetic architecture is often described as monogenic, oligogenic or polygenic, meaning that 
one, few or many genetic variants contribute to phenotypic variability, respectively.19 In addition 
to this, a recent theoretical development in the modelling of genetic architecture has suggested 
that all complex traits and diseases share a single ‘omnigenic’ architecture.20 This model 
suggests that gene regulatory networks may be sufficiently interconnected to allow all genes 
expressed in a disease-relevant cell to contribute to the disease phenotype. The omnigenic 
model posits that thousands of ‘non-core’ or ‘peripheral’ genes exert non-zero effects on 
essentially all downstream phenotypes.20 An omnigenic architecture would help explain the 
complexity of genetic architecture, and it draws parallels to the ‘infinitesimal model’21, in which 
all variants have a non-zero but small role in phenotypic variation. The omnigenic model also 
extends the idea of ‘universal pleiotropy’, which suggests that all characteristics are quantitative 
since, in principle, variation anywhere in the genome affects processes that are intimately 
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related to all others.22 These broad labels have been useful in theorizing the nature of genetic 
architecture, but modern techniques will enable the collection of data that will provide empirical 
evidence to instruct the description of genetic architecture.  
 
In this Review, rather than categorizing the genetic architecture of many diseases and traits, we 
describe different types of genetic architecture, how they can be assessed, and why genetic 
architecture is important in biology and in the clinic. We then highlight some factors that 
influence genetic architecture before outlining outstanding challenges and opportunities in 
obtaining a more complete understanding of genetic architecture and translating this to patient 
care. It should be noted that we can only comment on genetic architectures that have been 
observed to date and we acknowledge that these observed architectures will change as the field 
evolves.  
 
[H1] Types of genetic architecture 
Whether a trait or disease has a monogenic, oligogenic, polygenic or omnigenic architecture, 
there is variability in the nature of the genetic contributions to phenotype. This variability is likely 
to be a function of both differences or deficiencies in phenotypic measurement and genuine 
biological heterogeneity. Hence, the number of discovered genetic variants, and the variety of 
other attributes that contribute to genetic architecture, can vary substantially between diseases. 
 
To illustrate this, the genetic architecture of two well-studied diseases, type 1 diabetes mellitus 
and type 2 diabetes mellitus, can be compared (Figure 1a). Both diseases lead to 
hyperglycaemia, but type 1 diabetes mellitus is a disease of autoimmune dysregulation that 
leads to pancreatic β-cell dysfunction, whereas type 2 diabetes mellitus results from insulin 
resistance and relative insulin insufficiency.23 Type 1 diabetes mellitus is polygenic and 
associated with low frequency and common variants that have comparatively large effects on 
disease risk, relative to other complex diseases.24 By contrast, the risk of type 2 diabetes 
mellitus is associated with many genetic variants that have small effects on disease 
susceptibility.25,26 As recent large-scale sequencing studies have not identified low frequency or 
rare variants of large effect associated with type 2 diabetes mellitus,27 current data suggest that 
type 2 diabetes mellitus has a different genetic architecture to type 1 diabetes mellitus. The 
distinct pathophysiological mechanisms leading to these diseases may have evolved 
separately, leading to different architectures (see below). Since type 1 diabetes mellitus has a 
subset of observed variants that have a large effect on disease risk, genetics may help identify 
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individuals at risk for this disease, providing the opportunity to influence disease progression 
(see below).  
 
In contrast to diseases, biochemical traits are typically more proximally related to the function of 
a gene than complex diseases and common single nucleotide polymorphisms [G] (SNPs), taken 
together, are thought to contribute importantly to population-level variance.28 However, 
biochemical traits may still have highly divergent observed architectures. For example, the 
biochemical traits of low density lipoprotein (LDL) cholesterol and 25-hydroxyvitamin D levels 
are both ~50% heritable [G] according to classical twin studies.29,30 A GWAS of over 33,000 
individuals found that only four loci were associated with the level of 25-hydroxyvitamin D.31 One 
recent study looked for low-frequency and rare variants associated with low levels of vitamin D 
in 39,000 individuals through deep imputation32, and a second recent study searched for 
additional novel common variants associated with vitamin D levels in 79,366 individuals;33 these 
studies identified only four additional loci that are associated with 25-hydroxyvitamin D levels. 
Thus, the observed architecture of vitamin D level, at current sample sizes, is oligogenic and the 
associated genetic variants have comparatively large effects. By contrast, the level of LDL 
cholesterol seems to be influenced by many genetic variants with a broader distribution of effect 
sizes (Figure 1b).34 In a study from the Global Lipids Consortium involving 188,577 individuals 
of European ancestry, 52 loci were associated with the level of LDL cholesterol.34 Although the 
number of individuals in the study of LDL was larger than the number of individuals in the study 
of 25-hydroxyvitamin D, a smaller GWAS for LDL cholesterol levels in 19,000 individuals 
identified 11 LDL-associated loci,35 again suggesting, within the capabilities of existing studies, 
that these two biochemical traits with similar heritability have fundamentally different genetic 
architectures. Importantly, these comparisons between traits are limited by differences in 
sample size, which can impact observed genetic architecture. For example, schizophrenia had 
few associated common genetic variants at samples of several hundred cases,36 but at a 
sample size of tens of thousands, 113 genome-wide significant loci were observed.37 
 
Even the same trait measured at different anatomical sites can have a divergent genetic 
architecture. For example, bone mineral density, a clinically relevant risk factor for osteoporotic 
fracture,38 can be measured at different skeletal sites and is highly heritable.39 Measuring bone 
mineral density at the forearm in 5,672 individuals identified only one locus associated with this 
trait. This locus contained the genes WNT16 (encoding WNT16) and CPED1 (encoding 
Cadherin-like and PC-esterase domain-containing protein 1).40 Doubling this sample size 
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identified no new loci, but did find a low frequency variant with a large effect size of 0.46 
standard deviations per effect allele at the same WNT16–CPED1 locus.41 The same trait 
measured at the lumbar spine produces a contrasting genetic architecture; 19 independent loci 
were identified from 25,225 individuals, but the largest effect size of a single variant was only 
0.22 standard deviations.41 Although this difference in architecture could be a function of the 
different sample sizes, the available data suggest that architecture arising from common 
variants of highly similar traits can be remarkably different, and that these differences can be 
difficult to predict.  
 
[H1] How to assess genetic architecture 
The optimal conditions for elucidating genetic architecture are only achieved when all variable 
genotypes in the genome are measured in large populations in parallel with appropriate 
phenotyping. Although these conditions have not yet been achieved uniformly, studies have 
progressed towards this goal.27,42–44 GWAS data make it possible to estimate the number of 
undiscovered additive genetic associations that contribute to the genetic architecture of a trait.45 
Such estimates can provide guidance when deciding whether to pursue WES and/or WGS after 
a large GWAS has generally described the effect of common variants. However, for some 
polygenic and complex traits a multi-pronged analysis is likely to be needed to elucidate genetic 
architecture.42 Using triglyceride levels as an example, we describe an approach to partially 
resolve the architecture of a polygenic, complex trait. 
 
GWAS has identified many common variants of varying effect size for lipid levels.34 In the case 
of triglycerides (which are a type of lipid), targeted genotyping,46 GWAS,47 WES48 and WGS49 
have identified common variants of small effect as well as rare variants of larger effect that are 
associated with triglyceride levels and that are located in and near APOC3, the gene encoding 
apolipoprotein C3. The identification of large and small effect size variants at the same gene 
allows scientists to create a dose-response curve of genetic variants, where the effect of the 
genetic variant on protein function is plotted against the effect on phenotype; this curve helps to 
predict how pharmaceuticals targeted at the phenotype will affect the drug target.50 Although it is 
difficult to draw direct comparisons between the predictions made from short-term trials with 
those made on the basis of genetic effects that are often exerted over a lifetime, the exploitation 
of information like this for drug development is useful.51,52 Indeed, APOC3 has been 
therapeutically targeted using an antisense inhibitor of APOC3 synthesis, resulting in lowered 
triglyceride levels in humans, as would be predicted from the dose response curve.53 This 
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suggests that a mixed discovery strategy aimed at identifying small and large effect-sized 
variants may be beneficial to describing genetic architecture when many variants of varying 
effect size are implicated.  
 
As noted above, GWAS has been limited to common variants (MAF ≥5%), but variants with 
lower MAFs can now be estimated from genome-wide genotyping arrays using accurate deep 
imputation, which leverages the genotyping scaffold available from genome-wide genotyping to 
impute missing genetic variation at millions of additional genomic sites.54 This is achieved by 
comparing the haplotypes [G] observed in individuals subjected to genome-wide genotyping to 
those seen in an imputation reference panel [G] , which is a set of haplotypes derived from 
WGS.54 Through deep imputation, adequately powered GWAS can capture, in samples from 
individuals of European ancestry, the contribution to genetic architecture of genotypes with a 
MAF of approximately ≥0.1%.42 WES and WGS are generally used to explore the contribution of 
genetic variants with a MAF lower than 0.1%. However, WES and WGS genetic association 
mapping strategies suffer from low statistical power since single SNV association test [G] power 
decreases as the minor allele becomes rarer. Furthermore, since WES and WGS are 
expensive, their sample sizes are generally small. This further decreases the statistical power to 
reliably identify associations using these study designs. 
 
To overcome the reduced statistical power of WES and WGS studies in assessing the 
contribution of rare genetic variants to human traits and disease, region-based testing [G] is 
often used to ‘collapse’ information across a genomic region and test the association of the 
region with the phenotype; this strategy aims to improve statistical power.55 However, these 
tests have important limitations (Box 2) and thus have not often led to new insights. 
 
Prior to the population-based sequencing era, it was anticipated that low frequency and rare 
genetic variants would display very large effect sizes and hence explain some of the missing 
heritability (that is, heritability that cannot be explained by common SNVs).56 However, testing 
low frequency and rare genetic variants separately has revealed that they are not always 
associated with large effect sizes. For example, the UK10K project used single SNV association 
tests for >13 million SNVs with a MAF ≥0.1% to test their association with more than 30 traits in 
3,781 individuals.41 The study had 80% statistical power to detect associations for alleles with 
effect sizes of at least ~1.2 standard deviations on the trait at genetic variants with MAF as low 
as 0.5%. There was little evidence that alleles with a MAF in this range had effects on traits 
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larger than anticipated based on the power curve threshold (Figure 2; where the power curve 
defines the bound of statistical power, given the effect size and MAF). By contrast, several 
larger studies relying on single SNV association testing together with deep imputation have 
identified novel associations of large effect between low frequency variants and common traits, 
such as bone mineral density in the GEFOS Consortium, height in the GIANT Consortium and 
lipid levels in the Global Lipids Consortium.41,57–59 As the field progresses towards larger sample 
sizes, through the availability of resources such as UKBiobank and TopMed, increasingly rare 
genetic variants with larger effect sizes are likely to be identified from single SNV association 
testing. We anticipate that, of the methods currently available, this method will enhance our 
knowledge of genetic architecture the most. Of note, it has been suggested that common 
genetic variant signals may be explained by their synthetic association with rare genetic 
variants.60 Although this is a logical hypothesis, and some synthetic associations between 
common genetic variant signals and rare genetic variants have been observed,10 most common 
variants to date have not been found to be driven by synthetic associations.61,62 
 
[H1] When is genetic architecture important?  
Genetic architecture is important for screening for and diagnosing disease, enhancing biological 
understanding, drug development, Mendelian randomization and the scientific pursuit of gene 
mapping. Here we describe the role of genetic architecture in each of these aspects of human 
genetics. 
 
[H3] Screening and diagnosis. 
The genetic architecture of a disease can influence both an individual’s susceptibility to the 
disease and the variance in the population that can be explained by genetic factors.63 Here we 
try to disentangle these concepts, which are often conflated. 
 
An individual’s genetic susceptibility to disease is the sum of the effects of independent disease-
causing genetic variants and their interactions, and it is independent of the frequency of the 
disease-causing alleles in the population. However, variance explained [G] in the population 
depends on the number of disease-causing alleles and their frequencies and effect sizes, and it 
is thus a function of genetic architecture. One commonly-used measure of variance explained 
assumes that: the variants contribute to the additive genetic variance component only; that 
variants have small effect sizes, such that linearity approximately holds (that is,  the cumulative 
effect of all variants can be approximated by their sum); and that the variant ‘is’ the causal 
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variant (that is, its association with the phenotype is not mediated through another variant in 
linkage disequilibrium [G] ).64–66 The proportion of variance explained, under these assumptions, 
has been expressed for continuous phenotypes as 2𝑝(1 − 𝑝)𝛽2, where 𝑝 is the effect allele 
frequency, and 𝛽 is the effect of the allele on a standardized phenotype that has a mean of zero 
and a variance of 1. Thus, the frequency of the disease-associated allele helps explain variation 
in the population, even though it is not relevant when describing an individual’s susceptibility to 
disease. This has important implications for the use of genetic architecture in the diagnosis, 
prognosis and treatment of human diseases. 
 
The utility of a diagnostic test is often evaluated by assessing the area under a receiver operator 
curve [G] (ROC), which combines information from the sensitivity and specificity of a test for a 
binary outcome. Variance explained influences the specificity and sensitivity of genetic 
diagnostic tests and this is reflected in ROCs; as more variance in a phenotype is explained the 
area under the ROC will increase.63 As the amount of variance explained by genetic factors for 
most common diseases is currently low, the clinical utility of a ROC based on genetic factors is 
low. For example, a genetic risk score for osteoporosis in a study employing genetic variants 
that explained 5.8% of variance in bone mineral density (the clinically-relevant marker of 
osteoporosis) indicated a risk of osteoporosis that was not importantly different from the risk that 
would be expected by chance.67 However, variance explained by genetic factors in rare 
monogenic diseases such as cystic fibrosis can approach 100%.68 Consequently, at present, 
disease-associated genetic variants can be used to diagnose cystic fibrosis but not 
osteoporosis. 69 The reason for this difference in clinical care is due to the amount of variance 
explained by the known genetic variants. Further, the accuracy of a diagnostic test will increase 
with the prevalence of the disease in the population. Note that in this Review we define 
accuracy as the proportion of all diagnostic test results (both positive and negative) that are 
correct.  
 
Thus, genetics can aid the diagnosis of rare diseases in which most phenotypic variation is 
explained by known and highly penetrant genetic variants. However, the genetic architecture of 
most common diseases does not currently permit the use of genetics in diagnosis and 
screening, due to low variance explained. This situation will change as the variance explained in 
common disease risk by SNVs increases as the sample size of gene mapping studies 
increases, thus enabling the detection of smaller effects from common variants and larger 
effects from low-frequency and rare variants.70   
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[H3] Biological understanding and drug development.  
Some have suggested that the small amount of variance explained for most common SNPs for 
common diseases precludes their utility in drug target identification. This concept can be 
misguided in the absence of further information about the genetic architecture of the disease 
association. In order to understand the relevance of a small effect size SNP to drug 
development, one must first understand the effect of that SNP on protein level or function. Even 
if a SNP has a small effect on protein level and disease risk, this protein may still be a suitable 
target for disease prevention. This is because a small effect on protein level which translates to 
a small effect on disease risk may be consistent with a large effect on protein level which 
translates to a large effect on disease risk. Similarly, if a drug has a small effect on a protein 
level and has a small effect on disease risk, it remains possible that a drug having a larger effect 
on protein level may have a larger effect on disease risk. Further, such small effect sizes from 
SNPs may be particularly informative if the SNP has a large effect on protein level and no effect 
on disease risk. In such situations, the protein would consequently be less attractive as a drug 
target.  
 
The clinical effect of drugs on LDL cholesterol level and cystic fibrosis illustrate the dichotomy 
between variation explained and its utility to drug development. The activity of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (HMG-CoA reductase) partially determines the level of 
circulating LDL cholesterol.71 Pharmacological inhibition of HMG-CoA reductase reduces the 
level of LDL cholesterol by approximately 30–40%, which reduces the incidence of coronary 
heart disease.72 The common SNP most strongly associated with LDL cholesterol level near 
HMGCR, the gene encoding HMG-CoA reductase, explains 0.26% of the variance in LDL 
cholesterol level, which is clearly a small amount (rs12916, MAF 0.4).34 Thus, even though the 
HMG-CoA reductase locus harbours a common genetic variant that explains only a small 
amount of phenotypic variation, the pharmacologic inhibition of HMG-CoA reductase is clinically 
beneficial. Indeed there are many other reported cases in which genetic variants near the drug 
target have small effects on the phenotype, yet pharmacological manipulation of the drug target 
has profound effects on phenotype.73 For example, common variants near PCSK9, the gene 
encoding proprotein convertase subtilisin/kexin type 9 (PCSK9), have small effects on LDL 
cholesterol level74 whereas pharmacological inhibition of PCSK9 has large effects.75 
Furthermore, RANKL, the gene encoding receptor activator of nuclear factor κ-B ligand 
(RANKL), harbours common variants of small effect on bone mineral density,67 yet 
  11 
pharmacological inhibition of RANKL has large effects on bone mineral density.76 Thus, small 
effect size SNPs can serve to highlight proteins that, when targeted with large effect size 
pharmaceuticals, can have large effects on disease risk. 
 
As a contrasting example, nearly all patients with cystic fibrosis have mutations in CFTR, thus 
the variance explained by genetic variation in CFTR approaches 100%.68 However, despite the 
discovery of the association between CFTR and cystic fibrosis in 1989, the only drug targeting 
cystic fibrosis transmembrane conductance regulator (CFTR) was approved 23 years later and 
is partially efficacious in only 4.4% of cystic fibrosis patients.77 Therefore, even when nearly 
100% of the phenotypic variance [G] is explained by a few genetic variants at a single gene, 
pharmacologic therapies against the identified gene may not immediately advance patient care. 
 
The amount of variance explained by a genetic variant does not always correlate with the 
suitability of the gene as a therapeutic target because drugs work on proteins; the base pair 
associated with the disease serves to help identify the causal protein. The relevance of the 
variation explained to the clinic should be measured by assessing the effect of pharmacological 
agents on the protein and its resultant effect on disease. Furthermore, a gene which has no 
variants that are associated with a disease, perhaps because natural selection makes such 
perturbing genetic variants so rare that they lack statistical power for such an association, could 
still be a good drug target.  
How would a truly omnigenic architecture affect drug development? If all expressed genes in a 
cell that influences a phenotype had equivalent effects on phenotypic variance, then 
pharmacological manipulation of any of the expressed proteins would have an impact on the 
phenotype. This situation is unlikely as most drugs fail in drug development pipelines because 
they do not affect the phenotype, despite evidence of their engagement with the drug target.78 
Thus, there must be a gradient of effect of the impact of different proteins on phenotype, where 
some genes have large effects and other genes have smaller effects. This suggests that a set of 
‘core’ genes must have a more pronounced effect on phenotype and that the proteins derived 
from these genes will drive pharmaceutical development.  
  
[H3] Mendelian randomization. 
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Mendelian randomization is an established genetic epidemiology method that can provide 
evidence supporting, or contradicting, the causality of a risk factor in disease.79 This method 
uses SNVs as proxies for risk factors and can help to address confounding [G] and reverse 
causation [G]. Confounding is theoretically prevented in this method since SNVs are randomly 
allocated at conception, thereby breaking their association with factors not in the causal 
pathway. This situation is similar to the randomization process which prevents confounding in a 
randomized trial. Reverse causation is eliminated in this method since SNV allocation always 
precedes disease onset and cannot be altered by it. One of the main assumptions of Mendelian 
randomization is an absence of horizontal pleiotropy [G] , in which the genetic variant influences 
the outcome in a manner independent of the risk factor. Horizontal pleiotropy is distinct from 
vertical pleiotropy [G] ; the latter is defined as the association of the genetic variant with other 
traits in the same pathway due to its effect on the risk factor.80,81 Mendelian randomization 
studies rely upon vertical pleiotropy, but can be biased by horizontal pleiotropy. Knowledge of 
genetic architecture can help to detect the presence of pleiotropy and to guard against it.  
 
A polygenic architecture provides the opportunity to undertake sensitivity testing to identify the 
presence of horizontal pleiotropy through the Mendelian randomization-Egger (MR-Egger) 
test,82 (reviewed elsewhere).83 MR-Egger aims to account for, and address, the presence of 
unbalanced horizontal pleiotropy by assessing whether the intercept is different from the origin 
when plotting the relationship between the SNV on the outcome versus the SNV on the 
exposure. Unbalanced horizontal pleiotropy would lead to SNVs with a systematically higher or 
lower effect on the outcome than on the exposure, as they act upon the outcome through 
exposure-independent pathways. An omnigenic genetic architecture has implications for 
Mendelian randomization because it suggests universal pleiotropy in the human genome, 
however whether omnigenic pleiotropy is horizontal and balanced, horizontal and unbalanced, 
or vertical must be considered.  
 
It has been suggested that omnigenic pleiotropy violates Mendelian randomization assumptions 
when two phenotypes with omnigenic architectures are influenced by the same tissue type as 
this situation would result in horizontal pleiotropy18. However in one example for bone tissue 
(Figure 3), current data strongly suggest that unbalanced horizontal pleiotropy does not exist in 
two highly polygenic (and possibly omnigenic) traits, bone mineral density and height, both of 
which are influenced by the same tissue.  
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Beyond the omnigenic model, it is clear that the expression of certain genes in some cells 
causes meaningful biological changes in other cells. Indeed, signalling molecules dominate in 
endocrinology, whereby complex homeostatic feedback systems regulate many central 
biological processes. For example, insulin secreted by the pancreas causes glucose uptake in 
different cell types, such as skeletal muscle.85 These are examples of vertical pleiotropy, but not 
horizontal pleiotropy, and therefore do not violate the assumptions of Mendelian randomization. 
[H1] What influences genetic architecture? 
Here we describe some of the major factors that influence genetic architecture and discuss how 
understanding these determinants of architecture can help to improve our understanding of the 
genetic determinants of common diseases and traits. 
  
[H3] Phenotype. 
Phenotypes vary in how they relate to underlying genetic variation, their interaction with the 
environment, and by the quality of their measurement; all of these parameters contribute to 
observed genetic architecture. In contrast to genuinely polygenic complex traits, some 
molecular traits or medical conditions can have relatively large portions of variance predicted by 
one or a few relatively large genetic contributions. Examples of these molecular traits include 
the levels of C-reactive protein and86 uric acid,87 and age-related macular degeneration.88 In 
cardiovascular disease, rare variants of large effect can lead to severe monogenically controlled 
lipid disorders89, and there are several other polygenic traits for which heritability is high but the 
number of major contributing loci is relatively low (reviewed in reference 86).90 Measurement 
can also introduce complexity. For example, when measuring educational attainment,91 the 
observable phenotype (that is, years of schooling or college attendance) is likely to capture 
many factors marking a collection of biological pathways that contributed to the analysed 
outcome. Consequently, in the presence of adequate analytical power, the architecture of this 
trait will have polygenic characteristics as a result of the broad-spectrum measurement. 
This relationship between the measurement of phenotype and genetic architecture has 
implications for the interpretation and utilization of genetic variation in applied genetic and 
epidemiological analyses. The extent of horizontal pleiotropy92 can be estimated and analytical 
methods can use genetic associations to assess the overlap in heritable contribution between 
traits; for example linkage disequilibrium score regression93 can assess shared, narrow-sense 
heritability. However, these analyses [Au:OK? Or, please clarify ‘these’] cannot change what 
has been measured. Our limited approaches to population-based phenotyping are likely to 
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produce situations whereby apparently different traits in any given study are actually distal 
measures of the same underlying biological events. In this case, it is measurement that has 
shaped our interpretation of shared genetic architecture and a perceived phenotypic 
dependence is a consequence of the difficulty in directly measuring biology. 
 
[H3] Selection.  
Selection is the evolutionary process by which the frequency of genetic variation changes in 
response to a fitness consequence in the local environment. We will show examples where 
genetic architecture may have been influenced by the nature of the trait of interest, the relative 
age and effect of the mutations that explain its variation, and the characteristics of the 
population being assessed, contribute to selection and will influence genetic architecture. As a 
motivating example, common genetic variants with large effect could not exist if purifying 
selection removed them from the population42 (Figure 2). Although it is difficult to prove how 
selection has directly influenced genetic architecture, several natural experiments inform the 
relationship between complex trait genetic architecture and selection.  
 
Firstly, effective population size may influence observed genetic architecture by reducing the 
strength of selection94,95, allowing deleterious variants to increase in frequency by genetic drift 
(Figure 4a). Small population sizes allow variants of any frequency to change more rapidly —
akin to a founder effect [G] — and by chance, the frequency of some functional alleles can drift 
upwards so that they provide sufficient statistical power to detect their effect.96 Drift has been 
exploited by GWAS using isolated populations to enhance analytical power in otherwise limited 
sample sizes. An example of this is the Kosrae Pacific island population, individuals of which 
have a high prevalence of type 2 diabetes mellitus, thought to be a consequence of a founder 
event.97 Further, the frequencies of variants that cause type 2 diabetes mellitus had likewise 
changed in this population compared with populations on nearby islands. However, little 
evidence of different effect sizes from individuals of European descent was found, meaning that 
any individual possessing a given variant of the allele has the same increase in risk of type 2 
diabetes mellitus, regardless of ancestry.97 Furthermore, genetic drift may contribute to 
differences in longevity between Greek island populations, despite similarities in culture.98 SNPs 
that both increase or decrease longevity can be found at corresponding frequency in such 
drifted populations.  
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Secondly, populations share different histories, which can affect genetic architecture (Figure 
4b). For example, infection prevalence naturally varies, resulting in differential selection over 
time99, and the genetic architecture of infectious disease resistance varies from Mendelian to 
highly complex.100 This genetic architecture can theoretically be linked to the diverse 
evolutionary responses of the immune system101. An important example is the human leukocyte 
antigen (HLA) locus, which encodes the major histocompatibility complex that allows the 
immune system to distinguish ‘self’ from ‘non-self’.102 As individuals with the same HLA variant 
will be susceptible to similar infectious disease strains, recombination at this locus (and 
observed variation at the level of the population) is structured to provide offspring with a 
different resistance phenotype to their parents.103 However, this has not occurred for resistance 
to human malaria, which is caused by the same variant that causes sickle cell disease.104 In this 
case, antagonistic horizontal pleiotropy has allowed sickle cell disease to be maintained at 
relatively high frequency in populations exposed to malaria.105 Horizontal pleiotropy appears to 
maintain phenotypic diversity across many culturally regulated human phenotypes.106 Over 
evolutionary timescales, we therefore expect genetic architecture to change where selection is 
strong and mutations arise.  
 
Determining the extent by which selection influences genetic architecture requires adequate 
measurement of variants under selection. Strategies to detect selection in the genomes of 
contemporary populations include examination of functional variation, allele frequency variation, 
population differences and haplotype profiles (reviewed elsewhere).107 These methods agree 
that strong and recent signatures of selection have radically altered the frequency profiles of 
specific variants; for example, lactase persistence [G] and haemoglobinopathy-linked malarial 
resistance have both been detected in this way108–111. Signals as young as 2,000 years may be 
detected in the patterns of singleton [G] variation.112 Strong selection acting on traits influences 
genetic architecture because the anticipated phenotypic effect for a SNP of a given frequency is 
distorted (Figure 4b) relative to the phenotypic effects that are predicted by the dose-response 
curve.  
 
Despite difficulties in measuring selection, many genetic variants might be subject to subtle 
selection mechanisms acting in a polygenic model. Evidence has emerged for a ‘coordinated 
shift in allele frequency’113 in, for example, height112 and educational attainment114 across 
different populations. Specifically, GWAS for complex traits in large population-based collections 
have yielded evidence for polygenic contributions to complex traits which also demonstrate 
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detectable and trait specific differences in allele frequency across populations (Figure 5).115,116 
Together, these observations are suggestive of polygenic selection, where even in the presence 
of relatively small phenotypic effects, coordinated action across many loci will ultimately have an 
effect on the genetic architecture of the trait in question.  
 
[H3] Decanalization.  
Canalization117 maintains physiologic homeostasis through plastic responses to environmental 
or endogenous perturbations. Important cellular systems with long evolutionary histories are 
likely to be canalized; for example, body temperature is regulated to remain constant regardless 
of environment in humans, but not in all species.118 Decanalization is the hypothetical process 
whereby well-canalized systems can be destabilized by changes in environment or by the 
introduction of large-effect size genetic variants.117 The decanalizing effect generated by strong 
perturbations of long-standing homeostatic processes can lead to disease.117 Here we provide 
examples of genetic and environmental decanalization that have led to specific genetic 
architectures. 
 
Genetic variants of large effect, which hypothetically should become rare through negative 
selection, may cause perturbations that cannot be physiologically adapted to, thereby creating 
decanalization events. The effect size of variants which drive decanalization events can, in fact, 
be substantially larger than the effect size predicted by their MAF41,42,57,119. For example, the 
changes in bone mineral density owing to low-frequency genetic variants associated near EN1 
(the gene encoding homeobox protein engrailed-1) are four-fold larger than the mean changes 
caused by common variants and are in excess of that expected for the frequency of the 
associated variant; this may therefore represent an example of genetic decanalization.41 An 
example of environmental decanalization is the large change in carbohydrate intake in Inuit (a 
group of culturally similar indigenous individuals inhabiting Arctic regions) after the introduction 
of Western diets over the past 60 years, which is thought to have precipitated the discovery of 
common alleles with a large effect on the risk of type 2 diabetes mellitus and glucose 
dysregulation (Box 3).120,121  
 
The interaction between canalization and selection can be used to understand complex traits 
(Figure 4c). Differences in selection across different populations enables admixture mapping 
[G] ,122 which provides an opportunity to further understand genetic architecture. Since admixed 
individuals carry different proportions of their ancestral population genomes, it is possible to 
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explore whether the effect size at a causal locus varies as a function of the ancestry proportions 
across the rest of the genome. This enables inference about whether causal variants act 
independently and additively, or if more complex relationships are likely. For example, consider 
a variant that affects a canalized phenotype. If other variants across the genome also affect the 
phenotype and further vary in frequency by population, then the detected effect size should 
depend on the ancestry mixture.121  
 
[H1] Gene and environment interactions [Au:OK to reduce length to <39 characters, 
including spaces?]  
The effect of a genetic variant may vary depending on the level of an environmental determinant 
of the trait (gene x environment interactions), or by the number of alleles at another genetic 
variant (gene x gene interactions). This is not a focus of this Review and it has been discussed 
elsewhere123; however, it should be noted that there is not yet strong evidence that gene x 
environment or gene x gene interactions play a predominant role in determining most complex 
phenotypes. For example, recent evidence suggests that amongst the potential environmental 
determinants of body mass index (BMI), which together explain 14% of phenotypic variation, 
there is only evidence for interactions between genotype and smoking.124 All other 
environmental determinants of BMI had genetic interactions effects of 1% or less of the total 
phenotypic variance. This finding is supported by a general deficit of replicated gene x 
environment interactions in the literature. Consequently, although some interactions must exist, 
as yet these do not explain a large proportion of phenotypic variance and therefore do not 
strongly influence observed genetic architecture. 
 
Migration studies are important for comparing genetic and environmental risk factors and their 
interaction. For diseases primarily related to lifestyle and diet, including obesity,125–127 heart 
disease,128 inflammatory bowel disease,129 tuberculosis,130 and several cancers,131,132 migrants 
transition between the risk associated with their original population and their assimilating 
population. Studying individuals that migrate allows researchers to explore the relative role of 
environment in each disease, and hence the conclusion varies depending on the genetic 
architecture and contribution of each. 
 
[H1] Summary and conclusions  
The scientific drive behind exploring and understanding genetic architecture follows a desire to 
explain and understand all of the genetic contributions to phenotypic variance, which has been a 
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goal in quantitative genetics for more than a century.21 It will become possible to empirically 
describe near-complete genetic architecture for some traits. Alongside a growing collection of 
analytical approaches addressing the phylogenetic relationships between complex traits and 
diseases,93 the availability of genetic and phenotypic data in increasingly large population-based 
studies, such as UKBiobank15, will inevitably add to our understanding of relative genetic 
contributions. 
 
A more complete understanding of the genetic architecture of complex traits and diseases will 
maximize the utility of human genetics in disease screening, diagnosis, prognosis and therapy. 
Importantly, variance explained is strongly related to genetic architecture but it is not essential 
for drug development and individual-level risk prediction. The past decade of gene mapping in 
complex traits and diseases has shown that their genetic architectures are highly variable and 
difficult to predict. Nonetheless, clear trends have emerged, demonstrating that phenotypes that 
are reliably and inexpensively measured and more proximal to the effects of genetic variation 
are more amenable to the tools used to dissect their genetic architecture. Subject to 
measurement, the ultimate architecture of many traits may well be infinitesimal21, and this will 
affect the clinical goals of genetics; however, some genes have more important roles in disease 
causation than others, and some of these genes can be targeted for drug development.51 Drug 
developers should always consider the effect of the SNV on the function of the encoded protein 
when assessing the magnitude of the SNV’s effect on disease risk. Small effect sizes of SNVs 
on disease can be highly relevant to drug development when they have large effects on protein 
level or function, suggesting that the protein target is not appropriate for that disease. 
Furthermore, small effect sizes of SNVs can also highlight proteins, the pharmacological 
manipulation of which has large effect sizes on disease. 
 
Finally, understanding how the forces of natural selection and decanalization have influenced 
differing architectures across populations will be particularly helpful as the field moves to more 
fully characterize architectures in non-European ancestries. Architecture can be most easily 
measured through single-base pair testing and this approach has produced most of the loci 
associated with traits and common diseases. By contrast, rare variant collapsing tests are 
difficult to define, interpret and compare across traits. Thus, most advances in understanding 
allelic architecture will likely arise in the short-term through single-base pair testing in very large 
populations. Many of the greatest challenges and rewards in human genetics over the next 
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decade will rely upon understanding genetic architecture to more fully appreciate the biologic 
mechanisms that translate varying architectures to disease susceptibility. 
 
 
References: 
1. Mackay, T. F. C. The Genetic Architecture of Quantitative Traits. Annu. Rev. Genet. 35, 
303–339 (2001). 
2. Gratten, J., Wray, N. R., Keller, M. C. & Visscher, P. M. Large-scale genomics unveils the 
genetic architecture of psychiatric disorders. Nat. Neurosci. 17, 782–90 (2014). 
3. Visscher, P. M., Hill, W. G. & Wray, N. R. Heritability in the genomics era--concepts and 
misconceptions. Nat. Rev. Genet. 9, 255–266 (2008). 
4. Hansen, T. F. The Evolution of Genetic Architecture. Annu. Rev. Ecol. Evol. Syst. 37, 
123–157 (2006). 
5. Frazer, K. A., Murray, S. S., Schork, N. J. & Topol, E. J. Human genetic variation and its 
contribution to complex traits. Nat. Rev. Genet. 10, 241–251 (2009). 
6. Alkan, C., Coe, B. P. & Eichler, E. E. Genome structural variation discovery and 
genotyping. Nat. Rev. Genet. 12, 363–376 (2011). 
7. Visscher, P. M. et al. 10 Years of GWAS Discovery: Biology, Function, and Translation. 
Am. J. Hum. Genet. 101, 5–22 (2017). 
8. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait 
associations. Nucleic Acids Res. 42, D1001-6 (2014). 
9. Schork, A. J. et al. All SNPs Are Not Created Equal: Genome-Wide Association Studies 
Reveal a Consistent Pattern of Enrichment among Functionally Annotated SNPs. PLoS 
Genet. 9, e1003449 (2013). 
10. Astle, W. J. et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to 
Common Complex Disease. Cell 167, 1415–1429.e19 (2016). 
11. Aguet, F. et al. Genetic effects on gene expression across human tissues. Nature 550, 
204–213 (2017). 
12. Clark, M. J. et al. Performance comparison of exome DNA sequencing technologies. Nat. 
Biotechnol. 29, 908–914 (2011). 
13. Zarrei, M., MacDonald, J. R., Merico, D. & Scherer, S. W. A copy number variation map 
of the human genome. Nat. Rev. Genet. 16, 172–183 (2015). 
14. Treangen, T. J. & Salzberg, S. L. Repetitive DNA and next-generation sequencing: 
computational challenges and solutions. Nat. Rev. Genet. 13, 36–46 (2011). 
  20 
15. Allen, N. E., Sudlow, C., Peakman, T. & Collins, R. UK Biobank Data: Come and Get It. 
Sci. Transl. Med. 6, 224ed4-224ed4 (2014). 
16. NIH. Trans-Omics for Precision Medicine (TOPMed) Program. (2017). 
17. Day, F. R. et al. Physical and neurobehavioral determinants of reproductive onset and 
success. Nat. Genet. 48, 617–623 (2016). 
18. Tenesa, A. & Haley, C. S. The heritability of human disease: estimation, uses and 
abuses. Nat. Rev. Genet. 14, 139–149 (2013). 
19. Badano, J. L. & Katsanis, N. Beyond Mendel: an evolving view of human genetic disease 
transmission. Nat. Rev. Genet. 3, 779–789 (2002). 
20. Boyle, E. A., Li, Y. I. & Pritchard, J. K. An Expanded View of Complex Traits: From 
Polygenic to Omnigenic. Cell 169, 1177–1186 (2017). 
21. Fisher, R. A. The correlation between relatives on the supposition of Mendelian 
inheritance. Proc. Roy. Soc. Edinburgh 52, 99–433. (1918). 
22. Kacser, H. & Burns, J. A. THE MOLECULAR BASIS OF DOMINANCE. Genetics 97, 639-
666 (1981). [Au: Page numbers OK?] 
23. Harris, M. I. Impaired glucose tolerance in the U.S. population. Diabetes Care 12, 464–74 
(1989). 
24. Polychronakos, C. & Li, Q. Understanding type 1 diabetes through genetics: advances 
and prospects. Nat. Rev. Genet. 12, 781–92 (2011). 
25. Morris, A. D. P. et al. Large-scale association analysis provides insights into the genetic 
architecture and pathophysiology of type 2 diabetes. Nat. Publ. Gr. 44, 981–990 (2012). 
26. Scott, R. A. et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in 
Europeans. Diabetes db161253 (2017). doi:10.2337/db16-1253 
27. Fuchsberger, C. The genetic architecture of type 2 diabetes. Nature (2016). 
doi:10.1038/nature18642 
28. Hindorff, L. a et al. Potential etiologic and functional implications of genome-wide 
association loci for human diseases and traits. Proc. Natl. Acad. Sci. U. S. A. 106, 9362–
9367 (2009). 
29. Pilia, G. et al. Heritability of Cardiovascular and Personality Traits in 6,148 Sardinians. 
PLoS Genet. 2, e132 (2006). 
30. Shea, M. K. et al. Genetic and non-genetic correlates of vitamins K and D. Eur. J. Clin. 
Nutr. 63, 458–64 (2009). 
31. Wang, T. J. et al. Common genetic determinants of vitamin D insufficiency: a genome-
wide association study. Lancet 376, 180–188 (2010). 
  21 
32. Manousaki, D. et al. Low-Frequency Synonymous Coding Variation in CYP2R1 Has 
Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis. Am. J. Hum. Genet. 
101, 227–238 (2017). 
33. Jiang, X. et al. The Genetic Architecture of Vitamin D. in American society of Human 
Genetics 
34. Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. Nat. 
Genet. 45, 1274–1283 (2013). 
35. Kathiresan, S. et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. 
Genet. 41, 56–65 (2009). 
36. O’Donovan, M. C. et al. Identification of loci associated with schizophrenia by genome-
wide association and follow-up. Nat. Genet. 40, 1053–1055 (2008). 
37. Li, Z. et al. Genome-wide association analysis identifies 30 new susceptibility loci for 
schizophrenia. Nat. Genet. (2017). doi:10.1038/ng.3973 
38. Kanis, J. A. et al. Interpretation and use of FRAX in clinical practice. Osteoporos. Int. 22, 
2395–2411 (2011). 
39. Arden, N. K., Baker, J., Hogg, C., Baan, K. & Spector, T. D. The heritability of bone 
mineral density, ultrasound of the calcaneus and hip axis length: a study of 
postmenopausal twins. J. Bone Miner. Res. 11, 530–534 (1996). 
40. Zheng, H.-F. F. et al. WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, 
Bone Strength, and Osteoporotic Fracture Risk. PLoS Genet. 8, e1002745 (2012). 
41. Zheng, H. et al. Whole-genome sequencing identifies EN1 as a determinant of bone 
density and fracture. Nature 526, 112–7 (2015). 
42. Walter, K. et al. The UK10K project identifies rare variants in health and disease. Nature 
526, 82–90 (2015). 
43. Sidore, C. et al. Genome sequencing elucidates Sardinian genetic architecture and 
augments association analyses for lipid and blood inflammatory markers. Nat. Genet. 47, 
1272–1281 (2015). 
44. Gudbjartsson, D. F. et al. Large-scale whole-genome sequencing of the Icelandic 
population. Nat. Genet. (2015). doi:10.1038/ng.3247 
45. Yang, J. et al. Genetic variance estimation with imputed variants finds negligible missing 
heritability for human height and body mass index. Nat. Genet. (2015). 
doi:10.1038/ng.3390 
46. Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G. & Tybjærg-Hansen, A. Loss-
of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 
  22 
371, 32–41 (2014). 
47. Kathiresan, S. et al. Six new loci associated with blood low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Publ. Gr. 
40, 189–197 (2008). 
48. Heart, N. & The TG and HDL Working Group of the Exome Sequencing Project, National 
Heart, Lung, and Blood Institute. Loss-of-Function Mutations in APOC3,Triglycerides, and 
Coronary Disease. N. Engl. J. Med. 140618140014007 (2014). 
doi:10.1056/NEJMoa1307095 
49. Timpson, N. J. et al. A rare variant in APOC3 is associated with plasma triglyceride and 
VLDL levels in Europeans. Nat. Commun. 5, 4871 (2014). 
50. Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through 
human genetics. Nat. Rev. Drug Discov. 12, 581–594 (2013). 
51. Nelson, M. R. et al. The support of human genetic evidence for approved drug 
indications. Nat. Genet. 47, 856–860 (2015). 
52. Ference, B. A., Majeed, F., Penumetcha, R., Flack, J. M. & Brook, R. D. Effect of 
naturally random allocation to lower low-density lipoprotein cholesterol on the risk of 
coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 
2 factorial Mendelian randomization study. J. Am. Coll. Cardiol. 65, 1552–61 (2015). 
53. Gaudet, D. et al. Antisense Inhibition of Apolipoprotein C-III in Patients with 
Hypertriglyceridemia. N. Engl. J. Med. 373, 438–47 (2015). 
54. McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. 
Genet. (2016). doi:10.1038/ng.3643 
55. Ladouceur, M., Dastani, Z., Aulchenko, Y. S., Greenwood, C. M. T. & Richards, J. B. The 
Empirical Power of Rare Variant Association Methods: Results from Sanger Sequencing 
in 1,998 Individuals. PLoS Genet. 8, e1002496 (2012). 
56. Bodmer, W. & Bonilla, C. Common and rare variants in multifactorial susceptibility to 
common diseases. Nat. Genet. 40, 695–701 (2008). 
57. Styrkarsdottir, U. et al. Nonsense mutation in the LGR4 gene is associated with several 
human diseases and other traits. Nature 497, 517–520 (2013). 
58. Tachmazidou, I. et al. Whole-Genome Sequencing Coupled to Imputation Discovers 
Genetic Signals for Anthropometric Traits. Am. J. Hum. Genet. 100, 865–884 (2017). 
59. Iotchkova, V. et al. Discovery and refinement of genetic loci associated with 
cardiometabolic risk using dense imputation maps. Nat. Genet. 48, 1303–1312 (2016). 
60. Dickson, S. P., Wang, K., Krantz, I., Hakonarson, H. & Goldstein, D. B. Rare Variants 
  23 
Create Synthetic Genome-Wide Associations. PLoS Biol. 8, e1000294 (2010). 
61. Wray, N. R., Purcell, S. M., Visscher, P. M., Richardson, A. & Sisay-Joof, F. Synthetic 
Associations Created by Rare Variants Do Not Explain Most GWAS Results. PLoS Biol. 
9, e1000579 (2011). 
62. Anderson, C. A., Soranzo, N., Zeggini, E., Barrett, J. C. & Lim, X. L. Synthetic 
associations are unlikely to account for many common disease genome-wide association 
signals. PLoS Biol. 9, e1000580 (2011). 
63. Wray, N. R. et al. Pitfalls of predicting complex traits from SNPs. Nat. Rev. Genet. 14, 
507–15 (2013). 
64. Witte, J. S., Visscher, P. M. & Wray, N. R. The contribution of genetic variants to disease 
depends on the ruler. Nat. Rev. Genet. 15, 765–776 (2014). 
65. Chapman, J. M., Cooper, J. D., Todd, J. A. & Clayton, D. G. Detecting disease 
associations due to linkage disequilibrium using haplotype tags: a class of tests and the 
determinants of statistical power. Hum. Hered. 56, 18–31 (2003). 
66. Spencer, C. C. A. et al. Designing Genome-Wide Association Studies: Sample Size, 
Power, Imputation, and the Choice of Genotyping Chip. PLoS Genet. 5, e1000477 
(2009). 
67. Estrada, K. et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and 
reveals 14 loci associated with risk of fracture. Nat. Genet. 44, 491–501 (2012). 
68. Collins, F. S. Cystic fibrosis: molecular biology and therapeutic implications. Science 256, 
774–9 (1992). 
69. Yankaskas, J. R., Marshall, B. C., Sufian, B., Simon, R. H. & Rodman, D. Cystic fibrosis 
adult care: consensus conference report. Chest 125, 1S–39S (2004). 
70. Kemp, J. et al.. Identification of 153 new loci associated with heel bone mineral density 
and functional involvement of GPC6 in osteoporosis. Nat. Genet. 49, 1468–1475 (2017). 
[Au: Updated reference OK?] 
71. Istvan, E. S. & Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA 
reductase. Science 292, 1160–4 (2001). 
72. Illingworth, D. R. et al. Comparative effects of lovastatin and niacin in primary 
hypercholesterolemia. A prospective trial. Arch. Intern. Med. 154, 1586–95 (1994). 
73. Richards, J. B., Zheng, H.-F. & Spector, T. D. Genetics of osteoporosis from genome-
wide association studies: advances and challenges. Nat. Rev. Genet. 13, 672–672 
(2012). 
74. Willer, C. J. et al. Newly identified loci that influence lipid concentrations and risk of 
  24 
coronary artery disease. Nat. Genet. 40, 161–9 (2008). 
75. Sullivan, D. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein 
cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308, 
2497–506 (2012). 
76. McClung, M. R. et al. Denosumab in postmenopausal women with low bone mineral 
density. N. Engl. J. Med. 354, 821–831 (2006). 
77. Jones, A. M. & Helm, J. M. Emerging treatments in cystic fibrosis. Drugs 69, 1903–10 
(2009). 
78. Arrowsmith, J. Trial watch: phase III and submission failures: 2007-2010. Nat. Rev. Drug 
Discov. 10, 87 (2011). 
79. Smith, G. D. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology 
contribute to understanding environmental determinants of disease? Int J Epidemiol 32, 
1–22 (2003). 
80. Burgess, S., Bowden, J., Fall, T., Ingelsson, E. & Thompson, S. G. Sensitivity Analyses 
for Robust Causal Inference from Mendelian Randomization Analyses with Multiple 
Genetic Variants. Epidemiology 28, 30–42 (2017). 
81. Solovieff, N., Cotsapas, C., Lee, P. H., Purcell, S. M. & Smoller, J. W. Pleiotropy in 
complex traits: challenges and strategies. Nat. Rev. Genet. 14, 483–95 (2013). 
82. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid 
instruments: effect estimation and bias detection through Egger regression. Int. J. 
Epidemiol. 512–525 (2015). doi:10.1093/ije/dyv080 
83. Holmes, M. V, Ala-korpela, M. & Smith, G. D. Mendelian randomization in 
cardiometabolic disease: challenges in evaluating causality. Nat. Rev. Cardiol. (2017). 
doi:10.1038/nrcardio.2017.78 
84. Wood, A. R. et al. Defining the role of common variation in the genomic and biological 
architecture of adult human height. Nat. Genet. 46, 1173–86 (2014). 
85. Leto, D. & Saltiel, A. R. Regulation of glucose transport by insulin: traffic control of 
GLUT4. Nat. Rev. Mol. Cell Biol. 13, 383–96 (2012). 
86. Dehghan, A. et al. Meta-analysis of genome-wide association studies in &gt;80 000 
subjects identifies multiple loci for C-reactive protein levels. Circulation 123, 731–8 
(2011). 
87. Merriman, T. R. An update on the genetic architecture of hyperuricemia and gout. Arthritis 
Res. Ther. 17, 98 (2015). 
88. Maller, J. et al. Common variation in three genes, including a noncoding variant in CFH, 
  25 
strongly influences risk of age-related macular degeneration. Nat. Genet. 38, 1055–1059 
(2006). 
89. Sasidhar, M. V., Reddy, S., Naik, A. & Naik, S. Genetics of coronary artery disease - A 
clinician’s perspective. Indian Heart Journal 66, 663–671 (2014). 
90. Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS discovery. 
Am. J. Hum. Genet. 90, 7–24 (2012). 
91. Rietveld, C. A. et al. GWAS of 126,559 individuals identifies genetic variants associated 
with educational attainment. Science 340, 1467–71 (2013). 
92. Hodgkin, J. Seven types of pleiotropy. International Journal of Developmental Biology 42, 
501–505 (1998). 
93. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from 
polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295 (2015). 
94. Hartl, D. L. & Clark, A. G. Principles of population genetics. (1997). 
95. Fu, Y. X. Statistical tests of neutrality of mutations against population growth, hitchhiking 
and background selection. Genetics 147, 915–925 (1997). 
96. Ramachandran, S. et al. Support from the relationship of genetic and geographic 
distance in human populations for a serial founder effect originating in Africa. Proc. Natl. 
Acad. Sci. 102, 15942–15947 (2005). 
97. Lowe, J. J. K. et al. Genome-Wide Association Studies in an Isolated Founder Population 
from the Pacific Island of Kosrae. PLoS Genet. 5, e1000365 (2009). 
98. Panoutsopoulou, K. et al. Genetic characterization of Greek population isolates reveals 
strong genetic drift at missense and trait-associated variants. Nat. Commun. 5, 5345 
(2014). 
99. Dowell, S. F. Seasonal Variation in Host Susceptibility and Cycles of Certain Infectious 
Diseases. Emerg. Infect. Dis. 7, 369–374 (2001). 
100. Cooke, G. S. & Hill, A. V. S. Genetics of susceptibitlity to human infectious disease. Nat. 
Rev. Genet. 2, 967–977 (2001). 
101. Kirschner, M. & Gerhart, J. Evolvability. Proc. Natl. Acad. Sci. U. S. A. 95, 8420–8427 
(1998). 
102. Martin, M. P. & Carrington, M. Immunogenetics of viral infections. Current Opinion in 
Immunology 17, 510–516 (2005). 
103. Jeffreys, a J., Kauppi, L. & Neumann, R. Intensely punctate meiotic recombination in the 
class II region of the major histocompatibility complex. Nat. Genet. 29, 217–222 (2001). 
104. Flint, J., Harding, R. M., Boyce, A. J. & Clegg, J. B. The population genetics of the 
  26 
haemoglobinopathies. Baillieres. Clin. Haematol. 11, 1–51 (1998). 
105. Carter, A. J. & Nguyen, A. Q. Antagonistic pleiotropy as a widespread mechanism for the 
maintenance of polymorphic disease alleles. BMC Med. Genet. 12, 160 (2011). 
106. Laland, K. N., Odling-Smee, J. & Myles, S. How culture shaped the human genome: 
bringing genetics and the human sciences together. Nat. Rev. Genet. 11, 137–148 
(2010). 
107. Sabeti, P. C. et al. Positive natural selection in the human lineage. Science 312, 1614–20 
(2006). 
108. Gerbault, P. et al. Evolution of lactase persistence: an example of human niche 
construction. Philos. Trans. R. Soc. B Biol. Sci. 366, 863–877 (2011). 
109. Charlesworth, D. Balancing selection and its effects on sequences in nearby genome 
regions. PLoS Genet. 2, 379–384 (2006). 
110. Hamblin, M. T. & Di Rienzo, A. Detection of the signature of natural selection in humans: 
evidence from the Duffy blood group locus. Am. J. Hum. Genet. 66, 1669–79 (2000). 
111. Currat, M. et al. Molecular analysis of the beta-globin gene cluster in the Niokholo 
Mandenka population reveals a recent origin of the beta(S) Senegal mutation. Am. J. 
Hum. Genet. 70, 207–223 (2002). 
112. Field, Y. et al. Detection of human adaptation during the past 2000 years. Science 354, 
760–764 (2016). 
113. Berg, J. J. & Coop, G. A Population Genetic Signal of Polygenic Adaptation. PLoS Genet. 
10, (2014). 
114. Kong, A. et al. Selection against variants in the genome associated with educational 
attainment. Proc. Natl. Acad. Sci. 114, E727–E732 (2017). 
115. Turchin, M. C. et al. Evidence of widespread selection on standing variation in Europe at 
height-associated SNPs. Nat. Genet. 44, 1015–9 (2012). 
116. Robinson, M. R. et al. Population genetic differentiation of height and body mass index 
across Europe. Nat. Genet. 47, 1357–1362 (2015). 
117. Gibson, G. Decanalization and the origin of complex disease. Nat. Rev. 10, 134–140 
(2009). 
118. Flatt, T. The Evolutionary Genetics of Canalization. Q. Rev. Biol. 80, 287–316 (2005). 
119. Marouli, E. et al. Rare and low-frequency coding variants alter human adult height. 
Nature (2017). doi:10.1038/nature21039 
120. Manousaki, D. et al. Toward precision medicine: TBC1D4 disruption is common among 
the inuit and leads to underdiagnosis of type 2 diabetes. Diabetes Care 39, 1889–1895 
  27 
(2016). 
121. Moltke, I. et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance 
and type 2 diabetes. Nature 512, 190–193 (2014). 
122. Smith, M. W. et al. A High-Density Admixture Map for Disease Gene Discovery in African 
Americans. Am. J. Hum. Genet. 74, 1001–1013 (2004). 
123. Clayton, D. G. Prediction and interaction in complex disease genetics: Experience in type 
1 diabetes. PLoS Genet. 5, 1–6 (2009). 
124. Robinson, M. R. et al. Genotype-covariate interaction effects and the heritability of adult 
body mass index. Nat. Publ. Gr. 49, 1174–1181 (2017). 
125. Curb, J. D. & Marcus, E. B. Body fat and obesity in Japanese Americans. Am. J. Clin. 
Nutr. 53, 1552S–1555S (1991). 
126. Delavari, M., Sønderlund, A. L., Swinburn, B., Mellor, D. & Renzaho, A. Acculturation and 
obesity among migrant populations in high income countries – a systematic review. BMC 
Public Health 13, 458 (2013). 
127. Murphy, M., Robertson, W. & Oyebode, O. Obesity in International Migrant Populations. 
Curr. Obes. Rep. (2017). doi:10.1007/s13679-017-0274-7 
128. Patel, J. V et al. Impact of migration on coronary heart disease risk factors: Comparison 
of Gujaratis in Britain and their contemporaries in villages of origin in India. 
Atherosclerosis 185, 297–306 (2006). 
129. Ko, Y., Butcher, R. & Leong, R. W. Epidemiological studies of migration and 
environmental risk factors in the inflammatory bowel diseases. World J. Gastroenterol. 
20, 1238–47 (2014). 
130. Pareek, M., Greenaway, C., Noori, T., Munoz, J. & Zenner, D. The impact of migration on 
tuberculosis epidemiology and control in high-income countries: a review. BMC Med. 14, 
48 (2016). 
131. Ziegler, R. G. et al. Migration patterns and breast cancer risk in Asian-American women. 
J. Natl. Cancer Inst. 85, 1819–1827 (1993). 
132. Le, G. M., Gomez, S. L., Clarke, C. A., Glaser, S. L. & West, D. W. Cancer incidence 
patterns among Vietnamese in the United States and Ha Noi, Vietnam. Int. J. Cancer 
102, 412–417 (2002). 
133. Bearn, A. G. & Miller, E. D. Archibald Garrod and the development of the concept of 
inborn errors of metabolism. Bull Hist Med 53, 315–28 ST–Archibald Garrod and the 
development (1979). 
134. Xu, C. et al. Estimating genome-wide significance for whole-genome sequencing studies. 
  28 
Genet. Epidemiol. 38, 281–290 (2014). 
135. Moutsianas, L. et al. The power of gene-based rare variant methods to detect disease-
associated variation and test hypotheses about complex disease. PLoS Genet. 11, 
e1005165 (2015). 
136. BANSAL, V., LIBIGER, O., TORKAMANI, A. & SCHORK, N. J. in Biocomputing 2011 76–
87 (WORLD SCIENTIFIC, 2010). doi:10.1142/9789814335058_0009 
137. Bansal, V., Libiger, O., Torkamani, A. & Schork, N. J. Statistical analysis strategies for 
association studies involving rare variants. Nat. Rev. Genet. 11, 773–785 (2010). 
138. Basu, S. & Pan, W. Comparison of statistical tests for disease association with rare 
variants. Genet. Epidemiol. 35, 606–19 (2011). 
139. Styrkarsdottir, U. et al. Severe osteoarthritis of the hand associates with common variants 
within the ALDH1A2 gene and with rare variants at 1p31. Nat. Publ. Gr. 46, 498–502 
(2014). 
140. Do, R. et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk 
for myocardial infarction. Nature 518, 102–6 (2015). 
141. Ladouceur, M., Zheng, H.-F., Greenwood, C. M. T. & Richards, J. B. Empirical power of 
very rare variants for common traits and disease: results from sanger sequencing 1998 
individuals. Eur. J. Hum. Genet. 21, 1027–1030 (2013). [Au: Page numbers OK?] 
142. Mancuso, N. et al. Integrating Gene Expression with Summary Association Statistics to 
Identify Genes Associated with 30 Complex Traits. Am. J. Hum. Genet. 100, 473–487 
(2017). 
143. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose 
concentration, and risk of vascular disease: a collaborative meta-analysis of 102 
prospective studies. Lancet 375, 2215–2222 (2010). 
144. Krogh, A. & Krogh, M. A study of the diet and metabolism of Eskimos undertaken in 1908 
on an expedition to Greenland. Meddelelser om Gronl. 41, 165–173 (1914). 
145. Mouratoff, G. J., Carroll, N. V & Scott, E. M. Diabetes mellitus in Eskimos. JAMA 199, 
107–112 (1967). 
146. Jorgensen, M. E. et al. Diabetes and impaired glucose tolerance among the inuit 
population of greenland. Diabetes Care 25, 1766–1771 (2002). 
147. Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 
diabetes. Nature 445, 881–5 (2007). 
148. Scott, R. a. et al. Large-scale association analyses identify new loci influencing glycemic 
traits and provide insight into the underlying biological pathways. 44, 991-1005 (2012). 
  29 
[Au: Page numbers OK?] 
149. Bradfield, J. P. et al. A genome-wide meta-analysis of six type 1 diabetes cohorts 
identifies multiple associated loci. PLoS Genet. 7, e1002293 (2011). [Au: Page numbers 
OK?] 
150. Li, J. Z. et al. Worldwide Human Relationships Inferred from Genome-Wide Patterns of 
Variation. Science (80-. ). 319, 1100–1104 (2008). 
151. Rosenberg, N. A. et al. Genetic structure of human populations. Science 298, 2381–5 
(2002). 
 
Acknowledgements: The authors wish to acknowledge Vincenzo Forgetta for his help drawing 
the figures. NJT is a Wellcome Trust Investigator (202802/Z/16/Z), a programme lead in the 
MRC Integrative Epidemiology Unit (MC_UU_12013/3) and works within the University of Bristol 
NIHR Biomedical Research Centre (BRC). CG has received funding from NSERC. DJL is 
funded by the Wellcome Trust under grant number WT104125MA. JBR receives support from 
the Canadian Institutes of Health Research, The Lady Davis Institute of the Jewish General 
Hospital and the Fonds du Recherche Santé Québec. 
 
Author Contributions  
N. J. T., C. M. T. G., D. J. L and J. B. R. researched data for article, contributed to discussion of 
the content, wrote the article and reviewed and/or edited the manuscript before submission. 
N.S. contributed to discussion of the content and reviewed and/or edited the manuscript before 
submission.  
 
Competing interests statement 
The authors declare no competing interests. 
 
Publisher's note 
Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations. 
 
Databases [CE/PE: Please add hyperlinks to the databases where they first appear in the main text] 
 
UKBiobank 
http://www.ukbiobank.ac.uk/ 
  30 
 
TopMed 
https://www.nhlbi.nih.gov/research/resources/nhlbi-precision-medicine-initiative/topmed 
 
GEFOS Consortium 
http://www.gefos.org 
 
UK10K  
https://www.uk10k.org/ 
 
GoT2D 
http://www.type2diabetesgenetics.org/projects/got2d 
 
T2D-GENES 
http://www.type2diabetesgenetics.org/projects/t2dGenes 
 
GIANT-Consortium  
http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium 
 
deCODE 
https://www.decode.com/ 
 
  
  31 
Box 1: What is genetic architecture? 
 
Genetic architecture refers to the landscape of genetic contributions to a given phenotype. It 
comprises the number of genetic variants that influence a phenotype, the size of their effects on 
the phenotype, the frequency of those variants in the population and their interactions with each 
other and the environment.2 This is fundamentally different to the absolute amount of 
phenotypic variability that is accounted for by heritable factors (Figure 1). We can illuminate this 
concept by comparing two extremely different heritable phenotypes: height and phenylketonuria. 
Height has a polygenic, or even omnigenic, architecture,20 the latter of which is similar in 
concept to an infinitesimal architecture.21 Height must be sufficiently distal from the genome and 
inclusive of many biological processes and causal genetic variants to have such a polygenic 
architecture. By contrast, phenylketonuria has a monogenic architecture: although heritability is 
high, the shape of this heritability is singular. In phenylketonuria, one ‘inborn error’133 is 
responsible for the heritable phenotypic variability and thus the trait measured must be proximal 
to that genetic change to guard it from other potential contributions. These two contrasting 
examples of genetic architecture differ in the tools needed to discover and describe them and in 
how they can be used in a research or clinical setting. Traits like height may reflect the 
existence of many, common, ancient and small contributions to a complex phenotype, which 
require large population based collections and genome-wide common variant data to detect and 
which may have use in studies of risk factor exposure through techniques such as Mendelian 
randomization. In contrast, phenylketonuria may reflect relatively recent and thus rare mutations 
that have avoided the rigor of time and selection and which require huge samples of sequence 
data or familial designs to detect, but they may also have immediate clinical or pharmaceutical 
implications. Importantly, the architecture of these traits cannot be reliably predicted by the 
assessment of heritability alone. We aim to explore genetic architecture here given lessons from 
both the genome-wide association study and next generation sequencing eras. Our aim is to 
highlight that there is likely to be great variability in the genetic architecture of given traits of 
interest and that this should be considered for three reasons. First, architecture should be a 
motivating factor for comprehensive genetic studies of many phenotypes with unlimited size. 
Second, study designs should be tailored to observed genetic architecture and finally, 
understanding architecture and its limitations directly informs the clinical goals of human 
genetics, which are to assist in diagnosis, prognosis and the identification of therapeutic targets. 
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Box 2: Limitations of region-based single nucleotide variant testing. 
Region-based testing, which is motivated by a desire to improve statistical power to detect rare 
SNVs, tests the association of a trait with genetic variation across a genomic region, rather than 
the association of a trait with specific genetic variant. Region-based have important limitations, 
including difficulty with replication since, in a region of interest, the number of genetic variants 
observed and their allele frequencies can differ substantially across cohorts, even in populations 
of similar ancestry. Use of these tests also presents other practical problems. First, region-
based tests should be optimized for a specific genetic architecture, but the complete genetic 
architecture of a trait or disease is not often known and will vary between populations, and the 
genetic loci will also exhibit differences in local allelic architecture for a given trait. Second, most 
of the genetic variants identified through whole-genome sequencing studies (WGS) may have 
no discernible effect on the selected phenotype, and the inclusion of large numbers of variants 
with no effect in a region-based test will reduce power.134 Third, the direction of effect of rare 
variants (that is, whether they increase or decrease the risk of the disease) is not always known 
and this reduces the power of some region-based tests. Last, the relative performance of 
different tests can vary across significance thresholds; hence, if only a small number of 
candidate loci are being examined, the optimal test statistic is likely to be different from a 
genome-wide analysis.135 Previous work has outlined additional assumptions built into region-
based testing.136–138  
 
These challenges were apparent in the UK10K cohort project as neither a burden test [G] nor a 
variance component test [G] could identify a single instance, across 60 traits, where a region-
based test could identify a region not already highlighted through single SNV testing42. This 
region-based testing included several strategies to combine variants across a genomic region: it 
combined variants <1 and <5% MAF separately and included only protein-coding regions and 
only regions with evidence of evolutionary conservation. These tests may have yielded null 
results because UK10K used low-coverage sequencing and imputation, which captured rare 
variants with high fidelity, but as it had lower sensitivity for singletons and doubletons [G] it 
could have missed contributions from these SNVs.42 Findings from the UK10K cohort project 
are also limited by the bounds of statistical power, given the study sample size. Nonetheless, 
region-based testing did not contribute to our understanding of genetic architecture in this study. 
 
Other large sequencing-based studies have employed region-based tests with limited success. 
The GoT2D and T2D-GENES consortia undertook WGS in 2,657 individuals of European 
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descent with and without type 2 diabetes mellitus, and whole-exome sequencing (WES) in 
12,940 individuals.27 No rare variants or regions were found to be associated with type 2 
diabetes mellitus in this programme. A recent assessment by the GIANT-Consortium of coding 
genetic variants associations with height in 711,428 individuals identified rare variants at 83 loci 
associated with height using single SNV testing, but only three novel regions were identified 
through region-based testing.119 Similarly, although WGS-based studies from deCODE have 
identified single-SNV associations, clear associations from region-based tests were not 
identified,139 and a WES program in 9,983 patients with early-onset myocardial infarction, 
identified only single-SNV associations.140 This is consistent with previous work demonstrating 
that the empirically observed power of region-based tests is low.141 A promising avenue of 
region-based testing is transcriptome-wide association testing,142 although over 80% of the 
region-based findings using this method were identified using simple single SNV association 
testing. 
 
It is not apparent how region-based testing could assess the presence of an omnigenic 
architecture, although a region-based test revealed an enrichment of association signal in 
different types of variants, stratified by presumed functional effect, which showed a stronger 
signal from SNPs residing in active chromatin.20  
 
The success of region-based testing methods may increase as larger studies can capture and 
annotate very rare variants in large groups of individuals. However, in our experience the most 
profitable strategy for finding low frequency or rare genetic variants with previously 
undiscovered contributions to genetic architecture is currently the use of single SNV association 
tests in large cohorts.119  
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Box 3: Decanalization can identify unusual genetic architectures.  
Decanalization occurs when there is a large environmental change that influences a biological 
system that is strongly canalized. Circulating glucose levels are strongly canalized and show 
little variation in a healthy state.143 However, a large environmental change in Inuit may have led 
to decanalization of glucose control, which subsequently provided an opportunity to identify an 
unusual genetic architecture for type 2 diabetes mellitus; in the Inuit, this genetic architecture 
includes a common variant (minor allele frequency (MAF) 0.17) that has a large effect on the 
risk of developing type 2 diabetes mellutis.121 Living in a reduced-carbohydrate environment, 
Inuit had a relatively low intake of carbohydrates prior to the introduction of Western diets (see 
the figure, part a). Recent estimates demonstrate a much higher proportion of carbohydrate 
intake in Inuit contemporary diets.144 This large environmental change may have resulted in a 
decanalization of glucose regulation, which may have contributed to a dramatic increase in the 
prevalence of type 2 diabetes mellitus amongst Inuit between 1967 and 2002 (see the figure, 
part b).145,146 A recent metabochip genome-wide association study for glucose levels 2 hours 
after the intake of glucose in an oral glucose tolerance test found that a common premature 
termination codon in TBC1D4, the gene encoding TBC1 domain family member 4, had a large 
effect on this phenotype in Inuit (see the figure, part c, which demonstrates the strong 
association signal with glucose levels after an oral glucose tolerance test arising on 
chromosome 13). This information led to different diagnostic strategies in this population, which 
aim to use oral glucose tolerance testing to more accurately diagnose type 2 diabetes mellitus in 
this population.121 By contrast, there are no common genetic variants of similarly large effect for 
type 2 diabetes mellitus in the European population.147 The unusually high effect-size common 
variant for glucose levels 2 hours after oral glucose identified in Inuit (in red; see the figure, part 
d) contrasts with the small effect size common variants identified for this phenotype in a 
European-ancestry population (in blue; see the figure, part d).121,148 These data suggest that 
decanalization can lead to unusual genetic architectures, particularly in historically isolated 
populations, such as Inuit. Graphs in parts a, b and d were generated using data published in 
references xxx, xxx and xxx, respectively. Part c was reproduced, with permission, from 
reference 121.  
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Figure 1. Contrasting the observed genetic architecture of common diseases and 
biomedical traits. a) Genome-wide significant single nucleotide variants (SNVs) for type 1 
diabetes mellitus and type 2 diabetes mellitus are shown. Large genome-wide association 
studies (GWAS) show that these common diseases have contrasting observed genetic 
architectures. Type 1 diabetes mellitus is associated with common and low frequency genetic 
variants, some of which have relatively large effects on genetic architecture; these effects are 
measured in odds ratios, which give the odds of the outcome given exposure to one risk allele, 
compared to the odds of the outcome given exposure to no risk alleles.149 The genetic 
architecture of type 2 diabetes mellitus is shaped by, what are in general, smaller effect size 
common variants (which have a higher minor allele frequency (MAF)). [Au: higher than what? 
MAFs of larger effect size common variants?] The different architectures for diabetes type 1 
mellitus and type 2 diabetes mellitus impact the development of diagnostic tests and biologic 
validation of therapeutic targets for these diseases.25 b) Genome-wide significant SNVs for the 
biochemical traits Vitamin D (25OHD) and LDL cholesterol. Vitamin D, as measured by 25-
hydroxyvitamin D (25OHD) is associated with few genetic variants, some of which have 
relatively large effects.32 Only two new loci have been identified as being associated with 
25OHD, despite increasing the discovery sample size five-fold.33 Low density lipoprotein (LDL) 
cholesterol is associated with many more loci than 25OHD and these loci have a broader 
distribution of effect sizes than those associated with 25OHD.34 Beta is the additive effect of the 
minor alleles on the phenotype in standard deviations. Graphs in parts a and b were generated 
using data pubished in references xxx and xxx, respectively. 
 
Figure 2. Allelic spectrum for single marker association results for selected traits. A 
variant’s effect (absolute value of Beta, expressed in standard deviation units) is given as a 
function of minor allele frequency (MAF). The effect of each variant was assessed using single 
variant association tests, providing the effect of each variant, in standard deviation units, on the 
trait. Note that N is sample size and  is the multiple-testing corrected threshold to declare 
significance. Error bars are proportional to the standard error of the beta. Variants identifying 
known loci are shown in dark blue and variants identifying novel signals that have been 
replicated in independent studies are shown in light blue. The red and orange lines indicate 80% 
power at experiment wide significance level (p value ≤ 4.62x10-10) for the maximum theoretical 
sample size for the whole genome sequencing sample (red) and whole genome sequencing and 
genome-wide genotyping samples (orange) in the UK10K project.42 The observed deficit of 
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large-effect size rare variants will likely be overcome through larger sample sizes, as already 
observed for traits like bone mineral density.70 The main messages of this graph are that effect 
sizes increase with decreasing MAF, and that identified variants are not dramatically above 
what would be expected, given the power of the study. Figure reproduced, with permission, 
from reference 42 
 
Figure 3. Lack of unbalanced horizontal pleiotropy between bone mineral density and 
height using Mendelian randomization. The Mendelian randomization (MR)-Egger82 plot tests 
for the presence of unbalanced horizontal pleiotropy, which would violate a core assumption of 
Mendelian randomization. The two traits studied by genome-wide association studies (GWAS) 
are height84 and bone mineral density70. Both are highly polygenic and dependent upon the 
same tissue, bone. The omnigenic hypothesis suggests that widespread network pleiotropy 
would violate the pleiotropy assumption of Mendelian randomization if both the exposure and 
the outcome are complex traits dependent on the same tissue. To test whether omnigenic 
pleiotropy violates Mendelian randomization assumptions, we assessed the evidence for 
horizontal pleiotropy between bone mineral density and adult height, two polygenic phenotypes 
that are influenced by bone tissue and that have been subjected to large-scale GWAS. Using 
the largest published [Au:OK?] GWAS for bone mineral density (n = 142,487, using 169 
biallelic conditionally independent genome-wide significant independent SNVs)70 and adult 
height (n = 253,288),84 we tested for horizontal pleiotropy using MR-Egger, treating bone 
mineral density as the exposure and height as the outcome.82 However, this MR-Egger plot 
shows that there is no evidence of unbalanced horizontal pleiotropy, strongly suggesting a lack 
of network unbalanced horizontal pleiotropy that would violate Mendelian randomization 
assumptions. (The MR-Egger intercept is not different from zero: -0.002, 95% confidence 
intervals: -0.005, 0.001). For contrast, the inverse variance weighted results are shown, which 
constrain the line to intersect with the origin. GEFOS, genetic factors for osteoporosis; GIANT, 
genetic investigation of anthropometric traits. 
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Figure 4. Hypothetical departures from the ‘dose-response’ curve: Diagrams show the 
expected relationships between minor allele frequency (MAF) and the effect that variants may 
have on complex traits; this relationship defines the variation in genetic architecture between 
populations. a) Common single nucleotide polymorphisms (SNPs) are not expected to show 
strong effects on a phenotype as they would likely be deleterious and selected against to 
become rare. Therefore, a characteristic ‘dose-response’ curve, above which there are no 
variants, is expected. The shape of this curve can be determined by the effective population 
size and the number of samples in the dataset. A lower effective population size reduces the 
efficacy of selection, allowing greater variation in MAF. The points on the curve represent SNPs; 
the arrows show how they might move in a smaller population. b) Genomic architecture may 
differ by population. Here, population A experienced strong negative selection for the disease, 
reducing its incidence. Populations B and C retained the same mean trait but changed their 
genetic architecture by, for example, drift or pleiotropy. The selective origins of these differences 
may be inferred using historical allele frequencies. c) Most populations, for most traits, have the 
same effect size. However, some populations (shown here as X) may experience a higher 
measured effect size as a result of decanalization due to environmental pressure or because a 
small population size creates drift in the genetic structure that regulates the trait of interest. The 
different colours represent alternative states in each of the scenarios.  
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Figure 5: Difference between GWAS height loci across populations. a) A representation of 
allele frequency difference for height associated single nucleotide polymorphisms (SNPs) 
between North Europe and South Europe and African samples by their rank of effect size 
compared to the expected. This is a summary of previous work115 for [Au:OK?] sets of 500 
independent (r2 < 0.1) SNPs across the genome, sorted by GIANT height-association P value. 
Differences in population based minor allele frequency for many loci presents the potential for 
polygenic selection, which is shaping the genetic architecture of height. b) The relationship 
between genetic scores derived from the sum of sample allele frequencies, weighted by minor 
allele frequency for height based on existing GWAS data and composed in populations from the 
Human Gene Diversity Panel.150 Solid bars represent the actual genetic score for height 
calculated in each population in comparison to that predicted under a neutral model (with no 
marked population specific differences) and based on related populations (dashed bars).113 
Coloured areas represent the spread of sub-population specific estimates for genetic score 
nested within established population groupings.151 For an exemplar polygenic trait, these 
differences in genetic score illustrate potential evidence for polygenetic selection/adaptation. 
Figure in part a adapted, with permission, from reference 115. Figure in part b adapted, 
with permission, from reference 113.  
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Glossary: 
 
Heritable: A characteristic or trait that has a portion of variability that is accounted for by genetic 
factors.  
Phenotype: A measurable characteristic of an individual. 
Broad sense phenotypic heritability: The proportion of trait variance that is due to all genetic 
factors, including dominant and recessive factors as well as the interactions between genetic 
factors. Narrow sense heritability is the proportion of trait variance that is due to additive genetic 
factors.  
Complex traits: A trait that does not follow Mendelian inheritance patterns and is derived from 
any combination of multiple genetic factors, environmental factors and their interactions. 
Minor allele frequency: The frequency of the less frequent allele at a genetic variant in a 
population. The less frequent allele is referred to as the minor allele. 
Deep imputation: The use of large imputation reference panels to accurately estimate most 
low-frequency (1% ≤ MAF ≤ 5%) and rare (MAF < 1%) unobserved genetic variation in 
individuals who have been genome-wide genotyped. 
Phenotypic variance: The variance in a phenotype, which is often assumed to be a function of 
environmental and genetic factors, as well as their interactions. 
Single nucleotide polymorphisms (SNPs): Single base pair positions in the genome where 
two or more nucleotides occur commonly in the population. ‘Common’ is usually defined by at 
least 1% of the population carrying an alternative allele. Most often SNPs are biallelic, which 
means that the nucleotide will be one of two different alleles. 
Single nucleotide variants (SNV): Single base pair positions in the genome where there is 
variation across individuals. SNVs need not be biallelic or common. 
Genome-wide association studies (GWAS): Studies that test the association of all measured 
genetic variation across the genome with a trait or disease. GWAS usually tests the association 
of a phenotype with genetic variants that have a minor allele frequency (MAF) ≥1%, but deep 
imputation methods allow GWAS to test associations with variants at a lower MAF. 
Whole-exome sequencing (WES) studies: Studies that tests the association between genetic 
variation (usually SNVs) across the measured coding sequence of the genome with a trait or 
disease. WES can measure most coding genetic variants, regardless of minor allele frequency. 
Whole-genome sequencing (WGS) studies: Studies that test the association of genetic 
variation across the entire variable genetic sequence of the genome with a trait or disease. 
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WGS can measure most genetic variants present in the genome, regardless of minor allele 
frequency. However, certain regions are not usually measurable via sequencing, such as highly 
repetitive regions. 
Imputation reference panel: A dataset containing genetic information on a large number of 
individuals who have been whole-genome sequenced and had their haplotypes reconstructed. 
These haplotype panels enable accurate imputation of non-genotyped genetic variants in 
individuals who have undergone genome-wide genotyping. 
Haplotypes: A section of commonly varying or linked chromosomal material said to be in 
gametic phase, i.e. not punctuated by recombination at an appreciable population based 
frequency.  
Region-based testing: A single test of association between many genetic variants in a chosen 
region of the genome and a phenotype. 
Burden test: A class of region-based testing that collapses genetic variation into a single 
genetic score by measuring the total number of minor alleles across a genomic region. 
Variance component test: A single test of whether the phenotypic variance explained by a set 
of chosen genetic variants across a genomic region is zero. For example, a variance component 
test could be used to test whether all single nucleotide variants in a gene contribute to the 
variability in a phenotype. 
Single SNV association test: A genetic association test that tests variation at a single 
nucleotide variant with variation in a phenotype. This is the most common genetic association 
test and is frequently used for genome-wide genotyping data. 
Variance explained: The proportion of variance in a phenotype that is explained by a 
mathematical model. 
Linkage disequilibrium: The non-random association of alleles in a population. 
Receiver operator curve: A method to evaluate the performance of a diagnostic test for a 
binary outcome that plots the test’s sensitivity (the true positive rate) against one minus the 
test’s specificity (the false positive rate). 
Confounding: When the association between an exposure and an outcome is distorted by their 
associations with a third variable. A confounding variable is a variable that is associated with 
both the exposure and the outcome, but is not in the causal pathway between the two. A 
confounding variable could include a common cause of both the exposure and the outcome. 
Reverse causation: The phenomenon whereby the outcome influences the exposure. 
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Horizontal pleiotropy: In a Mendelian randomization study, horizontal pleiotropy is when the 
genetic variant influences the outcome in a manner independent of the risk factor. This is a 
violation of Mendelian randomization assumptions. 
Vertical pleiotropy: In a Mendelian randomization study, vertical pleiotropy is when the genetic 
variant influences the outcome through multiple biomarkers in the same pathway. This is not a 
violation of Mendelian randomization assumptions. 
Founder effect: Reduced genetic diversity that results when a population is descended from a 
small number of founders. 
Singleton: Genetic variant that is observed only once within the population studied. 
Doubletons: Genetic variants that are observed twice within the population studied. 
Lactase persistence: The continued activity of the enzyme lactase in adulthood in humans. 
Admixture mapping: A method of genetic association testing that relies on the admixture of 
populations, which occurs when individuals from two or more historically isolated populations 
interbreed.  
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Key points 
Genetic architecture of common diseases is central to the scientific and clinical goals of 
human genetics, because it directly impacts biology, disease screening diagnosis, 
prognosis and treatment. 
Genetic architecture is currently assessed by exploiting the differences in types of 
genetic variants measured through GWAS, WES and WGS. Each of these has its own 
merits and disadvantages, but all are subject to the limitations of sample size. Gene 
mapping studies should thus be tailored to the unique contributions of each of these 
technologies. 
To date, the observed genetic architecture of highly heritable diseases and traits differs 
markedly and cannot be reliably predicted. Where large sample sizes are available there 
still exist differences in detectable architecture.  
The concept of variance explained is not always relevant to individual-level risk 
prediction or drug development, whereas the genetic architecture of a given trait or 
disease can be more pertinent. 
Genetic architecture is variable in time and place and can be theoretically influenced by 
phenotypic measurement, selection and decanalization. 
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Interactions between genetic determinants of a trait or environmental influences 
contribute to genetic architecture. To date, few such interactions have been identified 
for most common diseases and traits, but this will likely change with increasing sample 
sizes. 
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ToC blurb  
Genetic architecture: The shape of genetic contribution to human traits and disease 
Nicholas Timpson, Celia M. T. Greenwood, Nicole Soranzo, Daniel J. Lawson, & J. Brent 
Richards  
Genetic architecture describes the characteristics of genetic variation that are responsible for 
phenotypic variability. This Review discusses the types of genetic architecture that have been 
observed, how they can be measured, and how genetic architecture informs the scientific and 
clinical goals of human genetics. 
 
